ProCE Banner Activity


Community Multidisciplinary Team Workshops on State-of-the Art Urothelial Carcinoma Management


Watch this CME/CNE/CPE-certified webcast from a live presentation by Terence Friedlander, MD, for an expert perspective on recent developments in the therapeutic landscape for muscle-invasive, locally advanced, and metastatic urothelial carcinoma

Pharmacists: 1.00 contact hour (0.1 CEUs)

Nurses: 1.00 Nursing contact hour

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: September 13, 2023

Expiration: September 12, 2024



Terence Friedlander

Terence Friedlander, MD

Professor of Medicine and Robert and Virginia O’Reilly Family Endowed Chair
Chief, Zuckerberg San Francsico General Hospital
Division of Hematology/Oncology
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from Astellas and Seagen.



Target Audience

This program is intended for physicians, nurses, pharmacists, and other healthcare professionals who treat and manage patients with UC.

Program Learning Goal

The goal of this activity is to improve the knowledge and competence of learners to integrate currently available and emerging therapies for treatment of UC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate into practice predictive biomarkers to inform personalized patient care

  • Plan adjuvant therapy for patients with high-risk urothelial carcinoma following radical resection

  • Integrate checkpoint inhibitor therapies into practice to optimize the care of patients with advanced urothelial carcinoma considering the available evidence and patient and disease characteristics

  • Select evidence-based targeted therapy approaches for patients with disease progression during or following platinum-containing chemotherapy and/or immune checkpoint inhibitor therapy

  • Incorporate guideline and expert recommendations to optimally manage adverse events associated with the use of immune checkpoint inhibitors
  • Navigate barriers and racial disparities in care to identify and enroll qualified patients in ongoing clinical trials actively investigating targeted systemic therapies and immune checkpoint inhibitor–based regimens for patients across the disease spectrum


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Terence Friedlander, MD

Professor of Medicine and Robert and Virginia O’Reilly Family Endowed Chair
Chief, Zuckerberg San Francsico General Hospital
Division of Hematology/Oncology
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Terence Friedlander, MD: consultant/advisor/speaker: AADi, Astellas, Seagen; researcher: Roche, Seagen, Trishula.

The planners and content peer reviewers from Clinical Care Options, LLC, do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from September 13, 2023, through September 12, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


The program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1  AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008176-0000-23-239-H01-P
Type of Activity: Application

Upon successfully completing the post-test with a score of 65 or better and the activity evaluation form, transcript information will be sent to NABP CPE Monitor Services within 60 days.